ABIRATERONE MYLAN 500 mg, film-coated tablet 60 tablets
Active ingredients: Abiraterone, Abiraterone acetate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ABIRATERONE MYLAN 500 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 60 plaquette(s) aluminium PVC polyéthylène PVDC de 1 comprimé(s)
- Marketing authorisation holder
- MYLAN PHARMACEUTICALS (IRLANDE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 8 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62375509CIP73024250CIP133400930242506Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ACÉTATE D'ABIRATÉRONEcomprimé | 500 mg · un comprimé | SA |
| ABIRATÉRONEcomprimé | 446 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.